Wrong email address or username
Wrong email address or username
Incorrect verification code
back to top
Search tags: Down-Syndrome
Load new posts () and activity
Like Reblog Comment
text 2018-09-11 11:29
Fragile X Syndrome Market

This report studies the global market size of Fragile X Syndrome in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Fragile X Syndrome in these regions.
This research report categorizes the global Fragile X Syndrome market by players/brands, region, type and application. This report also studies the global market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels, distributors and Porters Five Forces Analysis.

In 2017, the global Fragile X Syndrome market size was million US$ and is forecast to million US in 2025, growing at a CAGR of from 2018. The objectives of this study are to define, segment, and project the size of the Fragile X Syndrome market based on company, product type, application and key regions.

The various contributors involved in the value chain of Fragile X Syndrome include manufacturers, suppliers, distributors, intermediaries, and customers. The key manufacturers in the Fragile X Syndrome include
Aelis Farma SAS
Alcobra Ltd
AMO Pharma Limited
Confluence Pharmaceuticals LLC
Eli Lilly and Company
F. HoffmannLa Roche Ltd.
Marinus Pharmaceuticals, Inc.
MI.TO. Technology S.r.L.
Neuren Pharmaceuticals Limited
Ovid Therapeutics Inc.
Sage Therapeutics, Inc.
Zynerba Pharmaceuticals, Inc.

Market Size Split by Type
Market Size Split by Application
Research Center

Market size split by Region
North America
United States
South Korea
Central & South America
Rest of Central & South America
Middle East & Africa
GCC Countries
South Africa

The study objectives of this report are:
To study and analyze the global Fragile X Syndrome market size value & volume by company, key regions/countries, products and application, history data from 2013 to 2017, and forecast to 2025.
To understand the structure of Fragile X Syndrome market by identifying its various subsegments.
To share detailed information about the key factors influencing the growth of the market growth potential, opportunities, drivers, industryspecific challenges and risks.
Focuses on the key global Fragile X Syndrome manufacturers, to define, describe and analyze the sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.
To analyze the Fragile X Syndrome with respect to individual growth trends, future prospects, and their contribution to the total market.
To project the value and volume of Fragile X Syndrome submarkets, with respect to key regions along with their respective key countries.
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
To strategically profile the key players and comprehensively analyze their growth strategies.

In this study, the years considered to estimate the market size of Fragile X Syndrome are as follows:
History Year: 20132017
Base Year: 2017
Estimated Year: 2018
Forecast Year 2018 to 2025

This report includes the estimation of market size for value million US$ and volume K Pcs. Both topdown and bottomup approaches have been used to estimate and validate the market size of Fragile X Syndrome market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

For the data information by region, company, type and application, 2017 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Source: www.qandqmarketresearch.com
Like Reblog Comment
text 2018-05-28 13:50
Acute Respiratory Distress Syndrome Disease Pipeline Drugs Assessment: Clinical Trials Analysis, Player Profiles, Collaborations, Key Targets, Geographic Focus, and Data Publications, 2018

Acute Respiratory Distress Syndrome Disease Pipeline Drugs Assessment: Clinical Trials Analysis, Player Profiles, Collaborations, Key Targets, Geographic Focus, and Data Publications, 2018


Acute Respiratory Distress Syndrome Disease Pipeline Drugs Assessment: Clinical Trials Analysis, Player Profiles, Collaborations, Key Targets, Geographic Focus, and Data Publications, 2018


Acute Respiratory Distress Syndrome Disease Pipeline Drugs Assessment



Acute Respiratory Distress Syndrome is an acute lung dysfunction, which occurs as a result of injury or illness. It is known as adult respiratory distress syndrome, it may also affect children. In this condition small air sacs (alveoli) in lungs are accumulated with fluid which makes difficulty in passing of oxygen into blood stream. Symptoms of acute respiratory distress syndrome includes difficulty in breathing, rapid breathing, hyper ventilation. ARDS can be developed into deep infection which causes pneumonia, trauma.

ARDS can be diagnosed by blood tests, chest x-rays and others. Treatment for the ARDS are mechanical ventilation, supplemental oxygen, fluid management and a technique called positive end expiratory pressure (PEEP) to help push the fluid out of air sacs, extracorporeal membrane oxygenation, human mesenchymal stem cells.


A sample of this report is available upon request @




By Drugs, Acute Respiratory Distress Syndrome pipeline drugs are segmented as:

  • Interferon Beta-1a
  • Imatinib
  • Sivelestat
  • L-Citrulline
  • Poractantalfa
  • Ganciclovir
  • Others

By Route of Administration, Acute Respiratory Distress Syndrome pipeline drugs are segmented as:

  • Oral
  • Parenteral

By Trial Phase, Acute Respiratory Distress Syndrome pipeline drugs are segmented as:

  • Preclinical Trials
  • Phase 1
  • Phase 2
  • Phase 3
  • Phase 4

By Company, Acute Respiratory Distress Syndrome pipeline drugs are segmented as:

  • AltorBioScience
  • Genentech, Inc.
  • Faron Pharmaceuticals Ltd.
  • AltorBioScience
  • Suntory Pharmaceutical
  • Eli Lilly and Company
  • Asklepion Pharmaceuticals, LLC
  • BioMarck Pharmaceuticals, Ltd.
  • Others


Space Analysis:

  • In January 2016, Chiesi Farmaceutici S.p.A initiated phase II clinical trials of its CHF 5633 in neonatal respiratory distress syndrome.
  • In August 2017, BioMarck Pharmaceuticals initiated Phase-II clinical trials in Adult respiratory distress syndrome in USA (Inhalation)


To view TOC of this report is available upon request @




Report Description:

Acute Respiratory Distress Syndrome Disease Pipeline Drugs Assessment report studies the various therapeutics under clinical development for Acute Respiratory Distress Syndrome treatment along with targets for various drug candidate. The report provides plethora of information pertaining to trail phases, companies involved in the Acute Respiratory Distress Syndrome disease pipeline drugs development. This report studies the dynamics of the Acute Respiratory Distress Syndrome Disease Pipeline Drugs i.e. drivers, challenges and opportunities which are significantly impacting the product development. The report provides various information pertaining the clinical trials such as designation, grants, patents, and technology among others. Moreover, the report on Acute Respiratory Distress Syndrome disease pipeline drugs assessment comprehensively presents the geographic location, trial status information along with key players involved in the therapeutics development.


Need more information about this report @



Key Features of the Report:

  • Provides the information related to universities and research institutes working in the therapeutics development
  • Report comprehensively covers the all active and discontinued studies
  • Studies the entire pipeline with special emphasis on companies actively involved in the therapeutics development
  • Presents the prominent targets for drug development in each stage of clinical trial
  • Provides the in-depth analysis on the each drug candidates in the clinical trial phases


Get access to full summary @


About Precision Business Insights


Precision Business Insights is one of the leading market research and business consulting firm, which follow a holistic approach to solve needs of the clients. We adopt and implement proven research methodologies to achieve better results. We help our clients by providing actionable insights and strategies to make better decisions. We provide consulting, syndicated and customised market research services based on our client needs.


Contact to Precision Business Insights,


Kemp House,

152 – 160 City Road,

London EC1V 2NX


Email: sales@precisionbusinessinsights.com


Toll Free (US): +1-866-598-1553

Website @ https://www.precisionbusinessinsights.com


Like Reblog Comment
show activity (+)
review 2018-04-21 23:07
Gorgeous, fierce YA historic fiction
Sky in the Deep - Adrienne Young

Disclaimer: reviewing uncorrected pre-publication galley via NetGalley


This was an awesome read. To be honest, I decided to review it because it was getting so much prelaunch hype, but I kinda thought I wouldn't be the target audience. I really just couldn't care less about Vikings, and so much of the marketing around it emphasizes that element.


If you're in the same camp, not to worry. Sky in the Deep is incredibly well-done and tells an exciting, high-stakes story with a fierce multi-dimensional main character who goes through an incredible character arc and journey. I don't think it's positioned as fantasy, but to me, it felt as much like fantasy as historical fiction.


Eelyn is a warrior, and the book opens with her totally eviscerating guys in battle. Which . . . I wasn't that into. I think I was afraid she was going to be really flat, like some implausible, too-perfect super-warrior, but she becomes more of a sympathetic character pretty quickly because her dead brother shows up to the battle. So maybe she's crazy or in shock, but then he shows up again--and when she chases him, she gets captured by the enemy.


Eelyn lives by a sort of warriors' code and puts honour above all, so being taken captive and forced into slavery by the group they're perpetually feuding with is nearly grounds for suicide. However, this isn't really the story of Eelyn the Viking superhero shutting down the old-world slave trade. It's way more nuanced than that.


I really appreciated the slow development that shows how someone with a rigid view of the world could come to understand others and challenge her own beliefs and those of her family/community. The slow-burn romance wasn't bad either~~


I'm looking forward to seeing what else Adrienne Young has in store for us. This was a beautiful, powerful debut about a girl who's not only a wicked-strong warrior, but has the strength to learn, grow, and love others despite the cost.

Like Reblog Comment
text 2018-04-20 08:11
Global Dry Eye Syndrome Treatment Market: Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2012-2016 and Forecast 2017-2023

Dry Eye Syndrome Treatment Market: Dry eye syndrome (keratoconjunctivitis sicca), is an ocular disease caused by the lack of tear fluid to lubricate the eyes, which leads to problems in vision, tear film instability, and discomfort causes potential damage to the ocular surface. Dry eye syndrome can also cause due to other ocular surface diseases such as ocular allergy and meibomian gland dysfunction. The ocular surface contains 7 components including lacrimal and accessory lacrimal apparatus. Any abnormalities in one of the ocular surface components may cause the dry eye syndrome. Dry eye syndrome is classified into two types namely, evaporative dry eye and pure aqueous deficiency dry eye. The common symptoms associated with dry eye syndrome include ocular irritation, hyperaemia, mucoid discharge, blurred vision, excessive tearing, ocular dryness, photophobia, and grittiness. Dry eye syndrome is measured by a thin strip of filter paper placed at the edge of the eye, called a Schirmer test to measure the amount of tears present in the eye.



The global dry eye syndrome treatment market is expected to grow at a significant CAGR due to rise in the geriatric population (tear glands weaken due to aging and can’t produce sufficient tear fluid to maintain a lubricating film over the eyes) and increase in the prevalence of dry eye syndrome. The increase in the prevalence of diabetes, vitamin A deficiency, lupus, thyroid disorders, and rheumatoid arthritis might fuel the dry eye syndrome treatment market.  Moreover, increasing awareness among the population about diagnosis and treatment of dry eye syndrome, steady government support for medical research has allowed researchers to treat this condition more precisely and comprehensively, external stimuli such as laser eye surgery, and computer screen overuse are key factors also boosting the dry eye syndrome treatment market over the forecast period. However, expiration of blockbuster drug patents, the popularity of self-medication by patients is the major restraints for the dry eye syndrome treatment market over the forecast period.


A sample of this report is available upon request @




Dry eye syndrome treatment market segmented on the basis of treatment type, disease type, and distribution channel


Based on treatment type, dry eye syndrome treatment market has been segmented into the following:

  • Lubricant Eye Drops
    • Preservative-Free Drops
    • Oily Tear Eye Drops
    • Eye Ointments
  • Anti-inflammatory Drugs
    • Corticosteroids
    • Tetracyclines Oral
  • Autologous Serum Eye Drops
  • Nutrition supplements


Based on disease type, dry eye syndrome treatment market has been segmented into the following:

  • Evaporative dry eye syndrome
  • Aqueous dry eye syndrome


Based on distribution channel, dry eye syndrome treatment market has been segmented into the following:

  • Hospital pharmacies
  • Retail pharmacies
  • Online pharmacies
  • Others


To view TOC of this report is available upon request @




Global dry eye syndrome treatment market is in the developing stage owing to increase in the research and development activities by the competitors in the dry eye syndrome treatment market. The patents of various dry eye syndrome treatment drugs are in expiry stage, so various pharmaceutical companies are actively involved in the R&D of new drugs. Some of the key strategies followed by various pharmaceutical companies to increase revenue share in global dry eye syndrome treatment market including acquisitions & mergers, collaborations, and launching of new products. For instance, in July 2013, Novaliq GmbH won European approval for its lubricating, drug-delivering eye drop NovaTears, designed for over-the-counter treatment of dry eye syndrome. Similarly, in June 2015,  Allergan plc, a pharmaceutical company acquired Oculeve Inc, a medical device company that focuses on new technologies for dry eye disease to improve market position in the dry eye syndrome treatment market. In addition, in January 2017, Novaliq announced the positive top-line results of phase 2 clinical trial evaluating CyclASol in adults with moderate to severe dry eye disease. Moreover, in October 2015, Allergan plc launched artificial tear Refresh Optive gel drops to provide artificial tear option to relieve dry eye symptoms.


Need more information about this report @




Geographically, the dry eye syndrome treatment market has been segmented into following regions Viz. North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. North America dominates the dry eye syndrome treatment market due to high prevalence of lifestyle disorders which increase the chances of contracting dry eye syndrome, increase in the using medications such as antihistamines, pain relievers and antidepressants also increase the risk of dry eye syndrome in North America. Europe holds a dominant share in dry eye syndrome treatment market attributed to increase in the healthcare infrastructure, rise in the R&D activities, and increase in the usage of various medications which reduce the volume of tears produced in the eyes results in dry eye syndrome. Asia-Pacific is an emerging region in dry eye syndrome treatment market owing to increase in population majorly in India and China, strong government support in Asia-Pacific region.


Some of the players in dry eye syndrome treatment market are Novartis AG (Switzerland), Nicox (France), Allergan (U.S.), Santen Pharmaceutical Co., Ltd. (Japan), Otsuka Holdings Co., Ltd. (Japan), Auven Therapeutics (U.S.), AFT Pharmaceuticals (New Zealand), I-Med Pharma, Inc. (Canada), Sun Pharmaceuticals Industries Ltd. (India), Mimetogen Pharmaceuticals (U.S.), and Novaliq GMBH (Germany) to name a few.


Get access to full summary @




Source: www.precisionbusinessinsights.com/market-reports/global-dry-eye-syndrome-treatment-market
Like Reblog Comment
show activity (+)
review 2018-04-07 21:39
Review: Impostor Syndrome
Impostor Syndrome (The Arcadia Project) ... Impostor Syndrome (The Arcadia Project) - Mishell Baker

Book 3 of the Arcadia Project trilogy. I wasn't actually sure how many books would be in this series, but this reaches the kind of conclusion where, even if more books were added to the series, I'd still call the first three a trilogy. 


This book has the same excellent pacing and unreliable narrator as the previous two, but adds more locations to the mix. Both other parts of Earth and extended periods in Arcadia. There are also some new great characters and some excellent returning characters. And Caryl cannot handle any of it. Jesus, Caryl, what the fuck.


One of the things I love about this book is that I can't explain the story to you. In spite of the fast pace of the whole series, Baker has managed to integrate a ton of world building, and the plot in this one is constructed so deftly from those constructs that a summary would be unintelligible without having read the first two. There are heists? And high jinks? 


Another of the things that I love about this series is that it's heavily character driven. Even if watching the pieces of the plot come together weren't superb, I'd still be all over this series for the narrator. I'd read her narrate fucking up an Uber ride to the airport. 


The only thing I didn't love about this book was the interior vision quest sequence, but if Life Is Strange couldn't sell me on that concept, I doubt anyone else can.


A solid conclusion to a fun and interesting series. I'll be interested to see what Baker writes next.

More posts
Your Dashboard view:
Need help?